For research use only. Not for therapeutic Use.
AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC50s of 6 nM and 5000 nM for ERβ and ERα, respectively. AC-186 shows gender selective neuroprotective effects in a male rat model of Parkinson’s disease[1].
AC-186 (10 μM; 72 h) inhibits growth of LNCaP cells, and has no effect on PC3 cells[1].
AC-186 (10 mg/kg; s.c.; once) exhibits gender selective neuroprotective effects in a male rat model of Parkinson’s disease[1].
| Catalog Number | I000988 |
| CAS Number | 1421854-16-1 |
| Synonyms | 4-[4,4-difluoro-1-(2-fluorophenyl)cyclohexyl]phenol |
| Molecular Formula | C18H17F3O |
| Purity | ≥95% |
| InChI | InChI=1S/C18H17F3O/c19-16-4-2-1-3-15(16)17(9-11-18(20,21)12-10-17)13-5-7-14(22)8-6-13/h1-8,22H,9-12H2 |
| InChIKey | HSMUKSLNDJOZQG-UHFFFAOYSA-N |
| SMILES | C1CC(CCC1(C2=CC=C(C=C2)O)C3=CC=CC=C3F)(F)F |
| Reference | [1]. McFarland K, et al. AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson’s disease rat model. ACS Chem Neurosci. 2013 Sep 18;4(9):1249-55. [2]. Jian-Nong Ma, et al. Estrogen Receptor Beta Selective Agonists as Agents to Treat Chemotherapeutic-Induced Neuropathic Pain. ACS Chem Neurosci. 2016 Sep 21;7(9):1180-7. |
